What HGH Fragment 176-191 is
HGH Fragment 176-191 is a synthetic 16-residue peptide corresponding to the C-terminal region of human growth hormone (hGH). It was investigated in the context of research separating putative lipid-mobilising activity attributed to the C-terminus of hGH from its broader growth-promoting activity.
Molecular information
- Sequence origin: hGH residues 176-191
- Number of residues: 16
- Approximate monoisotopic mass: ~1817 Da (as the free acid)
- Physical form: Typically supplied as a white lyophilised powder
Areas of published research
Preclinical research has examined the peptide in adipocyte biology and lipid-metabolism research. Note: AOD-9604 is a modified version of this fragment with an additional stability-conferring residue; the two are distinct entities. Identity confirmation by LC-MS should distinguish HGH Fragment 176-191 from AOD-9604 by their characteristic mass difference.
Analytical considerations
Standard research-peptide analytical checks apply: identity confirmation by mass spectrometry (see LC-MS peptide testing explained), purity assessment by reversed-phase HPLC at 214 nm (see what is HPLC peptide testing), and batch-specific documentation (see how to read a peptide COA). Refer to the Peptovia Research Certificate of Analysis page for live examples of the analytical format used for batches supplied.
Further reading
Peer-reviewed literature on HGH Fragment 176-191 is accessible via PubMed and specialist journals. Readers are encouraged to evaluate primary sources directly rather than relying on secondary summaries.
Research Use Only. This profile is an educational overview of HGH Fragment 176-191 as a research peptide. It does not describe or recommend human, veterinary or clinical use. Peptovia Research supplies HGH Fragment 176-191 strictly for in-vitro laboratory research. No dosing, administration or therapeutic guidance is provided or implied.